You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

VANIQA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vaniqa, and what generic alternatives are available?

Vaniqa is a drug marketed by Skinmedica and is included in one NDA.

The generic ingredient in VANIQA is eflornithine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eflornithine hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VANIQA?
  • What are the global sales for VANIQA?
  • What is Average Wholesale Price for VANIQA?
Summary for VANIQA
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 80
Clinical Trials: 3
Patent Applications: 4,579
Drug Prices: Drug price information for VANIQA
What excipients (inactive ingredients) are in VANIQA?VANIQA excipients list
DailyMed Link:VANIQA at DailyMed
Drug patent expirations by year for VANIQA
Drug Prices for VANIQA

See drug prices for VANIQA

Recent Clinical Trials for VANIQA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Oncology GroupPhase 2
Bispebjerg HospitalPhase 4
National Cancer Institute (NCI)Phase 2

See all VANIQA clinical trials

US Patents and Regulatory Information for VANIQA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skinmedica VANIQA eflornithine hydrochloride CREAM;TOPICAL 021145-001 Jul 27, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VANIQA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Skinmedica VANIQA eflornithine hydrochloride CREAM;TOPICAL 021145-001 Jul 27, 2000 ⤷  Sign Up ⤷  Sign Up
Skinmedica VANIQA eflornithine hydrochloride CREAM;TOPICAL 021145-001 Jul 27, 2000 ⤷  Sign Up ⤷  Sign Up
Skinmedica VANIQA eflornithine hydrochloride CREAM;TOPICAL 021145-001 Jul 27, 2000 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VANIQA

See the table below for patents covering VANIQA around the world.

Country Patent Number Title Estimated Expiration
New Zealand 187536 -SUBSTITUTEDALKYL- -HALOMETHYL- -AMINOACET- IC ACIDS ⤷  Sign Up
Australia 4524393 ⤷  Sign Up
Japan S62500932 ⤷  Sign Up
Spain 2125339 ⤷  Sign Up
Germany 3585526 ⤷  Sign Up
Israel 54912 ⤷  Sign Up
South Africa 7803349 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.